Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) FCF Margin (2021 - 2025)

Historic FCF Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 13.77%.

  • Tarsus Pharmaceuticals' FCF Margin rose 323400.0% to 13.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.72%, marking a year-over-year increase of 627200.0%. This contributed to the annual value of 46.24% for FY2024, which is 6358000.0% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' FCF Margin stood at 13.77%, which was up 323400.0% from 29.6% recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' FCF Margin peaked at 563.79% during Q3 2021, and registered a low of 3667.16% during Q4 2021.
  • Over the past 5 years, Tarsus Pharmaceuticals' median FCF Margin value was 35.8% (recorded in 2021), while the average stood at 544.92%.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' FCF Margin in the last 5 years was 35571500bps (2022), contrasted with its biggest fall of -28300600bps (2022).
  • Tarsus Pharmaceuticals' FCF Margin (Quarter) stood at 3667.16% in 2021, then skyrocketed by 97bps to 110.01% in 2022, then plummeted by -173bps to 300.82% in 2023, then soared by 89bps to 33.51% in 2024, then soared by 141bps to 13.77% in 2025.
  • Its FCF Margin was 13.77% in Q3 2025, compared to 29.6% in Q2 2025 and 27.12% in Q1 2025.